Erik Kinnman is a seasoned life science executive with broad experience and understanding from the industry across a variety of businesses and functions. He has held a number of senior leadership positions in biopharmaceutical companies such as AstraZeneca and Sobi. His expertise and experience includes clinical development, business strategy, business development, and investor relations. Erik Kinnman also has experience from the financial sector. In addition, he holds an Executive MBA from the Stockholm School of Economics and has comprehensive scientific qualifications from the Karolinska Institutet, which has rendered him a Ph.D. and an Associate Professor. Moreover, Erik Kinnman is an M.D., board certified in Neurology and Pain Management.
“The NeuroVive Board and I are confident that Erik Kinnman is the right person to lead the company, its strategy, and leverage the opportunities. The combination of his strategic vision and medical expertise is an excellent fit with NeuroVive’s strategy refocused towards R&D. Erik Kinnman is a strong and experienced leader who has a proven ability to translate scientific, clinical and business strategy into execution," commented Gregory Batcheller, Chairman of the NeuroVive Board of Directors. "He will provide expertise and focus across the organization and establish solid partnerships that will enhance our R&D program further. His broad experience grounded in research, medicine and the biopharmaceutical industry is exactly what we need to lead this organization forward.”
“I am excited about NeuroVive, the CEO role, and the opportunity to contribute to the success and growth of the company. NeuroVive is a highly innovative organization and I am convinced that it has great potential in its range of novel treatment opportunities and their commercial potential. NeuroVive and its partners are truly led by a purpose and passion to make a difference and meaningful impact to patients affected by mitochondrial disorders. I will enable our researchers and partners to deliver on the opportunities in the clinical projects, as well as in the early pipeline to drive the value of NeuroVive.” says Erik Kinnman.
Erik Kinnman succeeds interim CEO Jan Nilsson, who will resume his position as Chief Operating Officer for NeuroVive. Jan has made significant contributions to move the organization forward. The recent partnership deals with both Isomerase and the University of Pennsylvania (UPENN) have been significant achievements under Jan’s leadership. Jan’s extensive NeuroVive knowledge and commitment to move the organization forward have been greatly appreciated by both the teams and board of NeuroVive.
NeuroVive Pharmaceutical AB (publ) is a pioneer in mitochondrial medicine and a company committed to the discovery and development of highly targeted candidates that preserve mitochondrial integrity and function in areas of significant therapeutic need. NeuroVive’s business approach is driven by value-adding partnerships with mitochondrial research institutions and commercial partners across the globe. NeuroVive’s portfolio consists of two clinical projects in acute kidney injury (AKI) and traumatic brain injury (TBI) with candidates in clinical and preclinical development and two drug discovery platforms. The NeuroSTAT® product has orphan drug status in Europe and in the US for treatment of moderate to severe traumatic brain injury and is currently being evaluated in a study, CHIC. Ciclosporin is being evaluated in an on-going study, CiPRICS, in acute kidney injury during major surgery. NeuroVive’s shares are listed on Nasdaq, Stockholm, Sweden.
For investor relations and media questions, please contact:
Christine Tadgell, NeuroVive, Tel: +46 (0)275 62 20 or email@example.com
It is also possible to arrange an interview with NeuroVive’s Chairman Gregory Batcheller at the above contacts.
NeuroVive Pharmaceutical AB (publ)
Medicon Village, SE-223 81 Lund, Sweden
Tel: +46 (0)46 275 62 20 (switchboard), Fax: +46 (0)46 888 83 48
NeuroVive Pharmaceutical AB (publ) is required to publish the information in this news release under The Swedish Securities Market Act. The information was submitted for publication on 23 February 2016, at 08 30 CET.